• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Stock Picks Are Hard to Find as Small-Caps Struggle

With poor breadth and money managers hiding in large-caps, I am being cautious, right now.
By JAMES "REV SHARK" DEPORRE
Jan 09, 2017 | 10:47 AM EST
Stocks quotes in this article: ARIA, WOOF, NVDA, ETRM, SINO, NLNK, PETX, TSLA, FB

The theme of the market action lately has been strength in large-cap technology names that drive the Nasdaq, while small-caps struggles. It is easy to see this in breadth, which has been running quite poorly despite relative strength in the senior indices. This morning, breadth is running more than 2 to 1 negative, but the Nasdaq 100 is positive.

What is going on here is that money managers are hiding in more-liquid large-cap names, while they try to pick up some performance against benchmarks. The way the market started the year left a lot of folks lagging and there is concern about getting too far behind too early.

A couple of big biotech mergers are driving ARIAD Phramaceutical (ARIA) and VCA  (WOOF)  -- and helping that sector. Recent momentum darling NVIDIA (NVDA) is active once again.

It is a very odd mix of action. There are a few pockets of speculation, such as Enteromedics (ETRM) , Sino-Global (SINO) and NewLink Genetics (NLNK) , but it requires very selective trading if you want to make progress.

Recently, I mentioned Aratana Therapeutics (PETX) is one of my top low-priced picks for 2017. The stock is attracting some attention this morning in sympathy with WOOF, as it is also an animal health play. The company should have some news fairly soon, and the technical pattern there looks attractive.

While I'm always hunting for the next stock picking, the poor breadth and small-cap struggles are making me quite cautious. I'm simply not finding much to trade aggressively -- and when that happens, I end up with higher levels of cash by default. I'm always focused on keeping my accounts as close to highs as possible, and that isn't easy right now -- unless I'm willing to chase something like Tesla (TSLA) or Action Alerts PLUS holding Facebook (FB) , which I'm not.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Rev Shark was long SINO and PETX, although positions may change at any time.

TAGS: Investing | U.S. Equity | Healthcare | Technology | Markets | Stocks

More from Healthcare

Boston Scientific Could Be Wicked Good in This Kind of Market

Brad Ginesin
May 24, 2022 2:13 PM EDT

Here's why this healthcare stock is a potential port in the storm for investors.

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login